AHR-1709
AHR-1709 is an experimental antipsychotic of the tryptamine family which was never marketed.
≈ 1 min read
AHR-1709. encyclopegia.org, snapshot enwiki-001378619088. /a/ahr-1709
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
AHR-1709 is an experimental antipsychotic of the tryptamine family which was never marketed. It is a cyclized tryptamine, more specifically an analogue of pip-tryptamine. AHR-1709 shows high affinity for the serotonin 5-HT 1A and 5-HT 2A receptors (K i = 27–44 nM and 4.8 nM, respectively) and for the dopamine D 2 receptor (K i = 81 nM).
It may act as a serotonin 5-HT 1A receptor antagonist. The drug also shows high affinity for ketanserin-labeled serotonin 5-HT 2A receptors (K i = 9.33–12.6 nM) and is a potent antagonist of these receptors (A 2 = 24.6–120 nM).
The drug produces antipsychotic-like effects in rodents, including reversal of hyperlocomotion but without induction of catalepsy, antagonism of stereotypy, or elevation of prolactin levels. AHR-1709 also produces antiemetic effects in rodents.
It is a derivative of the dopaminergic neurotoxin MPTP and is a weak dopamine reuptake inhibitor similarly but with 23-fold higher potency ( = 4,200 nM and 95,200 nM, respectively). However, unlike MPTP, AHR-1709 did not produce dopaminergic neurotoxicity in rodents.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1378619088 under CC BY-SA 4.0; modifications have been made.